An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05877599

Title field or adapter rule

{'original_value': 'An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:24.675174+00:00

Published At

2026-09-29T00:00:00+00:00

Record Updated At

2026-09-29

Source Retrieved At

2026-10-31T22:17:54.613222+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non-small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Colorectal Carcinoma", "Pancreatic Adenocarcinoma", "Breast Cancer", "Other Solid Tumors", "Ovarian Cancer", "Myeloid Neoplasms (AML/MDS)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-29", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT05877599"

protocolSection.identificationModule.officialTitle

"An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Colorectal Carcinoma (protocolSection.conditionsModule.conditions)
• Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Breast Cancer (protocolSection.conditionsModule.conditions)
• Other Solid Tumors (protocolSection.conditionsModule.conditions)
• Ovarian Cancer (protocolSection.conditionsModule.conditions)
• Myeloid Neoplasms (AML/MDS) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['NT-175 for advanced malignancies'], 'description': '* Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide\n* Single infusion Autologous, engineered T Cells targeting TP53 R175H\n* Post-infusion recombinant interleukin-2 (rIL-2)', 'name': 'NT-175', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.